
Virginia COVID-19 Surveillance Data Update


February 3, 2022



National: Weekly COVID-19 Case Rate

Updated 2/2/22

US COVID-19: 7-Day Case Rate per 100,000, by State/Territory



| | Cases in the Last 7 Days Per 100k Population |
|------------|--|
| Virginia | 699.6 (-28.2%) |
| U.S. | 941.1 (-29.9%) |
| Alaska | 2,103.5 (-29.6%) |
| Washington | 1,791.7 (-23.0%) |
| Kentucky | 1,690.1 (-11.6%) |


Our Neighbors

Rates Higher than Virginia

North Carolina, **1,174.5** (-20.9%)
West Virginia, **1,367.4** (-24.1%)
Tennessee **1,361.7** (-22.8%)
Kentucky, **1,690.1** (-11.6%)

Rates Lower than Virginia:


District of Columbia, **331.3** (-23.0%)
Maryland, **280.6** (-45.8%)



Compared to last week, **cases** decreased to 446,355 (7-day MA) per day (-35.9%)

Hospitalizations decreased to 17,133 (7-day MA) per day (-14.2%)

Deaths increased to 2,287 (7-day MA) per day (+4.6%)




Early U.K. Data Show Similar Vaccine Effectiveness Against Omicron Variant BA.1 and BA.2 Boosters Make A Substantial Difference

Updated 1/31/22

- U.K. Health Security Agency measured vaccine effectiveness against symptomatic disease following BA.2 infection in a test-negative case control design, as compared to the Omicron BA.1 sub-lineage
- **Key Takeaway:** Vaccine effectiveness against symptomatic disease was similar for BA.1 and BA.2 of Omicron.
- After 2 doses, **effectiveness was 9% (7-10%) and 13% (26-40%) respectively for BA.1 and BA.2, after 25+ weeks.** This increased to **63% (63-64%) for BA.1 and 70% (58-79%) for BA.2 at 2 weeks following a booster**

Table 3. Vaccine effectiveness against symptomatic disease (all vaccine brands combined) for BA.1 and BA.2. OR = odds ratio, VE = vaccine effectiveness.

| Dose | Interval after dose | BA.1 (VE (95% CI)) | BA.2 (VE (95% CI)) |
|------|---------------------|-----------------------|-----------------------|
| 2 | 25+ weeks | 9% (7-10) | 13% (-26-40) |
| 3 | 2+ weeks | 63% (63-64) | 70% (58-79) |




GISAID/NEXTSTRAIN/NCO, ADAPTED BY K. FRANKLIN/SCIENCE


Where has the BA.2 subvariant been detected?

And what percent (%) of new COVID-19 cases have been sequenced & reported over the past 30 days?

BA.2 sequences submitted 150 3000 Cases Sequenced % 0 0.1 0.25 0.5 0.75 1



Cases by Date of Symptom Onset, Past 13 weeks




Compared to last week, **cases decreased** to 7,895 (7-day MA) from 11,891 per day (-33.6%)


Hospitalizations decreased to 3,046 per day (-17.6%)

Deaths decreased to 43 per day (-48%)

Cases by Date Reported, All Reporting Timeline



COVID-19 in Virginia Hospitals



- Confirmed COVID-19 Patients Currently on Ventilator Support*
- ICU Hospitalizations (Confirmed + Pending)
- CONFIRMED Hospitalizations
- Total Current COVID Hospitalizations (Confirmed + Pending)
- 7 Day Moving Average of COVID-19 Current Hospitalizations (Confirmed + Pending)


- Compared to last week hospitalizations **decreased to 3,046** (7-day MA) from 3,639 (-16%)
- Compared to last week. ICU hospitalizations have **decreased to 506** from 588 (-14%)
- 321 patients are currently on ventilator support (-11%)

COVID-19 Burden in Virginia LTCFs

Key Trends


- There were **220 LTCF COVID-19 outbreaks reported in the past 30 days**: 70 in Eastern, 46 in Central, 45 in Northwest, 33 in Northern, and 26 in Southwest (see figure top right).
- The number of reported staff cases has declined in the past couple of weeks. The number of reported resident cases has continued to decline from the previous reporting week (see figure bottom right).
 - For the reporting week ending January 30, 2022, **926 resident and 815 staff cases were reported to NHSN**. Data for this reporting week are preliminary.
- For reporting week ending January 23, 2022, data reported by 283 nursing homes showed **89% of residents were fully vaccinated**; data reported by 283 nursing homes showed **91% of staff were fully vaccinated** (see figures bottom left).
 - Of the nursing home residents eligible to receive an additional dose or booster, 74% have received an additional dose or booster of COVID-19 vaccine.
 - Of the nursing home healthcare personnel eligible to receive an additional dose or booster, 42% have received an additional dose or booster of COVID-19 vaccine.

COVID-19 Booster Vaccination in Virginia Nursing Homes




Data were reported by 286 Virginia nursing homes into the National Healthcare Safety Network (NHSN) as of 2/01/2022 and are subject to change, including booster eligibility per [updated vaccine guidance](#). In Virginia, 283 nursing homes reported resident vaccination data for reporting week ending 1/23/2022; 283 nursing homes reported staff vaccination data for reporting week ending 1/23/2022. For staff type definitions, refer to [NHSN Table of Instructions](#).

Number and Region of LTCF COVID-19 Outbreaks by Date VDH Notified



Outbreaks reported from nursing homes, assisted living facilities, and multicare facilities to VDH with a confirmed or suspected etiologic agent of SARS-CoV-2. Data are from the Virginia Outbreak Surveillance System as of 01/31/2022 and are subject to change.

Nursing Home Resident and Staff COVID-19 Cases



Data are from NHSN as of 2/01/2022 and are subject to change. For reporting information, please refer to the NHSN data collection forms: [residents](#), [staff](#).

Metrics date: 1/30/2022

New cases per 100k within the last 7 days

% Positivity 7-day moving average

COVID-like ED visits rate per 100k

Central








Eastern

Far Southwest

Near Southwest

Northern

Northwest



| Burden | Level 0 | Level 1 | Level 2 | Level 3 | Level 4 |
|---------------|---------|---------|---------|---------|---------|
| New Cases | <10 | 10-49 | | 50-100 | >100 |
| % Positivity | <3 | 3-5 | 5-8 | 8-10 | >10 |
| CLI ED Visits | <4 | | 4-5.9 | | ≥6 |

| Symbol | Trend |
|--------|-------------|
| ↑ | Increasing |
| ↓ | Decreasing |
| ○ | Fluctuating |


Please note: the methods used this week have changed slightly; data is now compared from Sunday to Sunday instead of Wednesday to Wednesday

[Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020–January 2022 | CDC: January 28, 2022](#)

Summary: A study analyzing disease severity of Omicron compared to other high transmission periods by evaluating severity indicators: length of stay, ICU admissions, and death.

Key Findings: COVID-19 disease severity appears to be lower during the Omicron period than during previous periods of high transmission; deaths, ICU bed use, and ventilation were lower during Omicron than previous periods. However, there was a significantly higher volume of ED visits and hospitalizations (3.4x – 7.2x higher) during Omicron, which caused a strain on the US health care system.


FIGURE. Seven-day moving average number of COVID-19 cases, emergency department visits, hospital admissions, and deaths — United States,* December 1, 2020–January 15, 2022



[Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance August 2021–January 2022 | CDC: January 28, 2022](#)

Summary: A study evaluating effectiveness of a booster dose of mRNA against ED visits and hospitalizations among adults during the Delta and Omicron waves.

Key Findings: During both Delta- and Omicron-predominant periods, receipt of a **third vaccine dose was highly effective at preventing COVID-19–associated emergency department and urgent care encounters by 94% for Delta and 82% for Omicron** as well as **preventing COVID-19–associated hospitalizations by 94% for Delta and 90% for Omicron** respectively.




Virginia Vaccination by Age

- ✓ **74.3% (+0.5%)** of the Eligible (5+) Population and **70.0% (+2.8%)** of the Total Population are Fully Vaccinated
- ✓ **54.4%** of the Eligible Population and **30.3% (+2.3%)** of Total Population Vaccinated with 3rd Dose/Booster
- ✓ **39.2% (+11%)** of the Total Population is “Up-to-Date” with their Vaccinations
- ✓ **89.7% (+0.3%)** of the Adult (18+) Population and **54.0% (+1.7%)** of 5 to 17 year olds Vaccinated with at Least One Dose
- Green percent represents percent increase from two weeks prior


First Dose, Second Dose, and Booster Administrations Have Decreased

- Over the past 2 weeks, Third Dose/Booster Administrations have decreased by nearly 80%
- First and Second Dose Administrations have plateaued at an all-time-low

COVID-19 Vaccine Administration Moving Average by Dose Number




Federal doses not included in this number
Source: [COVID-19 Vaccine Summary – Coronavirus \(virginia.gov\)](#)



Source: [COVID-19 Vaccine Summary – Coronavirus \(virginia.gov\)](#)

Percent of the Total Population with at Least One Dose by Locality




First Dose Vaccination Rate by Region for Total Population

| Region Name | 1st Dose Vaccination |
|-------------|----------------------|
| Central | 68.2% |
| Eastern | 72.3% |
| Northern | 82.5% |
| Northwest | 65.3% |
| Southwest | 57.3% |

- 6 out of 133 Localities have a first dose vaccination rate below 50%
- 36 out of 133 Localities have a first dose vaccination rate above 70%
- There is a disparity across Urban and Rural areas by Age Groups, with Rural Adolescents the Lowest Vaccinated group

| 2013 SRHP Isserman Classification | 5 to 11 | 12 to 17 | 16 to 17 | 18 to 30 | 31 to 50 | 51 to 64 | 65+ | Grand Total |
|-----------------------------------|---------|----------|----------|----------|----------|----------|-----|-------------|
| Mixed Urban | 41% | 72% | 76% | 74% | 73% | 85% | 85% | 65% |
| Urban | 38% | 74% | 80% | 67% | 78% | 86% | 92% | 75% |
| Mixed Rural | 25% | 52% | 58% | 58% | 64% | 75% | 81% | 61% |
| Rural | 17% | 44% | 49% | 52% | 58% | 71% | 90% | 75% |
| Grand Total | 34% | 66% | 71% | 65% | 72% | 82% | 88% | 72% |



| | At Least One Dose* | Fully Vaccinated* |
|----------------|--------------------|-------------------|
| Nationwide | 75.4% (+0.4%) | 63.8% (+1.3%) |
| D.C. | 93.3% (+2.2%) | 70.1% (+1.9%) |
| Kentucky | 64.7% (+1.7%) | 55.7% (+1.3%) |
| Maryland | 83.7% (+1.6%) | 72.7% (+1.4%) |
| North Carolina | 80.9% (+2.1%) | 58.5% (+1.6%) |
| Tennessee | 60.7% (+1.7%) | 52.8% (+1.5%) |
| Virginia** | 83.2% (+3.0%) | 70.6% (+2.3%) |
| West Virginia | 63.6% (+1.3%) | 56.2% (+1.1%) |

*Total population, includes out-of-state vaccinations

**Differs from previous slide because all vaccination sources (e.g., federal) are included

*** Green percent represents percent increase from one weeks prior